Abstract

We herein report the synthesis, antioxidant power and neuroprotective properties of nine homo-bis-nitrones HBNs19 as alpha-phenyl-N-tert-butylnitrone (PBN) analogues for stroke therapy. In vitro neuroprotection studies of HBNs19 against Oligomycin A/Rotenone and in an oxygen-glucose-deprivation model of ischemia in human neuroblastoma cell cultures, indicate that (1Z,1′Z)-1,1′-(1,3-phenylene)bis(N-benzylmethanimine oxide) (HBN6) is a potent neuroprotective agent that prevents the decrease in neuronal metabolic activity (EC50 = 1.24 ± 0.39 μM) as well as necrotic and apoptotic cell death. HBN6 shows strong hydroxyl radical scavenger power (81%), and capacity to decrease superoxide production in human neuroblastoma cell cultures (maximal activity = 95.8 ± 3.6%), values significantly superior to the neuroprotective and antioxidant properties of the parent PBN. The higher neuroprotective ability of HBN6 has been rationalized by means of Density Functional Theory calculations. Calculated physicochemical and ADME properties confirmed HBN6 as a hit-agent showing suitable drug-like properties. Finally, the contribution of HBN6 to brain damage prevention was confirmed in a permanent MCAO setting by assessing infarct volume outcome 48 h after stroke in drug administered experimental animals, which provides evidence of a significant reduction of the brain lesion size and strongly suggests that HBN6 is a potential neuroprotective agent against stroke.

Details

Title
Synthesis, antioxidant properties and neuroprotection of α-phenyl-tert-butylnitrone derived HomoBisNitrones in in vitro and in vivo ischemia models
Author
Chamorro Beatriz 1 ; Diez-Iriepa, Daniel 2 ; Merás-Sáiz Belén 3 ; Chioua Mourad 3 ; García-Vieira, David 3 ; Iriepa Isabel 4 ; Hadjipavlou-Litina Dimitra 5 ; López-Muñoz, Francisco 6 ; Martínez-Murillo, Ricardo 7 ; Gonzàlez-Nieto, Daniel 8 ; Fernández, Israel 9 ; Marco-Contelles, José 3 ; Oset-Gasque, María Jesús 10 

 Complutense University of Madrid, Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Madrid, Spain (GRID:grid.4795.f) (ISNI:0000 0001 2157 7667); Camilo José Cela University of Madrid (UCJC), Faculty of Health, Madrid, Spain (GRID:grid.449750.b) (ISNI:0000 0004 1769 4416) 
 Institute of Organic Chemistry (CSIC), Laboratory of Medicinal Chemistry, Madrid, Spain (GRID:grid.418891.d) (ISNI:0000 0004 1804 5549); Alcalá University, Department of Organic Chemistry and Inorganic Chemistry, Alcalá de Henares, Madrid, Spain (GRID:grid.7159.a) (ISNI:0000 0004 1937 0239) 
 Institute of Organic Chemistry (CSIC), Laboratory of Medicinal Chemistry, Madrid, Spain (GRID:grid.418891.d) (ISNI:0000 0004 1804 5549) 
 Alcalá University, Department of Organic Chemistry and Inorganic Chemistry, Alcalá de Henares, Madrid, Spain (GRID:grid.7159.a) (ISNI:0000 0004 1937 0239); Alcalá University, Institute of Chemical Research Andrés M. del Río, Alcalá de Henares, Madrid, Spain (GRID:grid.7159.a) (ISNI:0000 0004 1937 0239) 
 Aristotle University of Thessaloniki, Department of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Thessaloniki, Greece (GRID:grid.4793.9) (ISNI:0000000109457005) 
 Camilo José Cela University of Madrid (UCJC), Faculty of Health, Madrid, Spain (GRID:grid.449750.b) (ISNI:0000 0004 1769 4416); “Hospital 12 de Octubre” Research Institute, Neuropsychopharmacology Unit, Madrid, Spain (GRID:grid.144756.5) (ISNI:0000 0001 1945 5329) 
 Cajal Institute (CSIC), Neurovascular Research Group, Department of Translational Neurobiology, Madrid, Spain (GRID:grid.419043.b) (ISNI:0000 0001 2177 5516) 
 Universidad Politécnica de Madrid, Center for Biomedical Technology (CTB), Madrid, Spain (GRID:grid.5690.a) (ISNI:0000 0001 2151 2978); Biomedical Research Networking Center in Bioengineering Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain (GRID:grid.5690.a) 
 Biomedical Research Networking Center in Bioengineering Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain (GRID:grid.5690.a); Universidad Complutense de Madrid, Departamento de Química Orgánica I and Centro de Innovación en Química Avanzada (ORFEO-CINQA), Facultad de Ciencias Químicas, Madrid, Spain (GRID:grid.4795.f) (ISNI:0000 0001 2157 7667) 
10  Complutense University of Madrid, Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Madrid, Spain (GRID:grid.4795.f) (ISNI:0000 0001 2157 7667); Universidad Complutense de Madrid, Instituto Universitario de Investigación en Neuroquímica, Madrid, Spain (GRID:grid.4795.f) (ISNI:0000 0001 2157 7667) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2436973888
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.